Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity

1 Apr 2008

Abstract excerpt

Knockout and transgenic studies in mice demonstrate that normal somatic tissues redundantly express 3 cyclin D proteins, whereas tumor cells seem dependent on a single overexpressed cyclin D. Thus, selective suppression of the individual cyclin D deregulated in a tumor represents a biologically valid approach to targeted cancer therapy. In multiple myeloma, overexpression of 1 of the cyclin D proteins is a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18431519
DOI: 10.1172/jci34149

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activityPMID 18431519Read ↗

RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastomaSemantic proximity Read ↗

Identification of novel small molecule inhibitors of centrosome clustering in cancer cellsSemantic proximity Read ↗

Ceftriaxone exerts antitumor effects in MYCN ‐driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repressionSemantic proximity Read ↗

Quinoline-5,8-Dione CDC25 Inhibitors: Potent Anti-Cancer Agents in Leukemia and Patient-Derived Colorectal OrganoidsSemantic proximity Read ↗

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast CancerSemantic proximity Read ↗

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastomaSemantic proximity Read ↗

Small Molecule Targeting the Hec1/Nek2 Mitotic Pathway Suppresses Tumor Cell Growth in Culture and in AnimalSemantic proximity Read ↗

Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in NeuroblastomaSemantic proximity Read ↗

Naringenin as a potential inhibitor of human cyclin-dependent kinase 6: Molecular and structural insights into anti-cancer therapeuticsSemantic proximity Read ↗

A cell competition-based drug screen identifies a novel compound that induces dual c-Myc depletion and p53 activationSemantic proximity Read ↗

Identification of Cytotoxic Drugs That Selectively Target Tumor Cells with MYC OverexpressionSemantic proximity Read ↗

Selective In Vivo and In Vitro Effects of a Small Molecule Inhibitor of Cyclin-Dependent Kinase 4Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.